{"name":"Sequential Medicine Ltd","slug":"sequential-medicine-ltd","ticker":"","exchange":"","domain":"","description":"Sequential Medicine Ltd is a biotechnology company focused on developing innovative treatments in the pharmaceutical space. The company has a strong pipeline with three key drugs, including two marketed products and one in Phase 3 trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"D+L","genericName":"D+L","slug":"d-l","indication":"Immune support and general wellness","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"SM-1","genericName":"SM-1","slug":"sm-1","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"D+Z","genericName":"D+Z","slug":"d-z","indication":"Chronic hepatitis C virus infection (genotype-independent)","status":"marketed"}]}],"pipeline":[{"name":"D+L","genericName":"D+L","slug":"d-l","phase":"marketed","mechanism":"D+L is a combination of vitamin D and L-theanine designed to support immune function and promote relaxation.","indications":["Immune support and general wellness"],"catalyst":""},{"name":"SM-1","genericName":"SM-1","slug":"sm-1","phase":"phase_3","mechanism":"SM-1 is a small molecule that targets the PD-1 receptor.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Metastatic melanoma"],"catalyst":""},{"name":"D+Z","genericName":"D+Z","slug":"d-z","phase":"marketed","mechanism":"D+Z is a fixed-dose combination of daclatasvir and sofosbuvir that inhibits hepatitis C virus NS5A and NS5B proteins to block viral replication.","indications":["Chronic hepatitis C virus infection (genotype-independent)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwJBVV95cUxPQ1pCbExpQ245bHFzVEphWWg4ekJKVkI1Y0E2NVotenN6N1BvNl82aFE1c3JNN2JXLUNvdmJTVlhNM3k0cjFnSl9oZks3cDhRd2JmYXM1S19MR1o1cmhWQ1B1MVJkOW1xaWFyRVU5clRRNzNQSDBrdjk4WWJsUWhUSzl5c1M2bG5YZ1ZBMkhPWndEVm5vc1Z5NG9tV1pMODZ4TUxqYzFkLTJlTmdtd09aV3QxZEhEX0RjdDMyYjJIMVVfRER0M2JFMEpBQWhyWG4xRmRkS2lYNHJDZnpacjZCWmlOUXQ0aVpfdlU1dUVNRkt1bzVzZkprUkU1VmUzX2R1QjhzSExxNnBIN0hHREVTN2VRV0E2b0hLMzZfYlo4UjJweWYwVTZGSXFhbmFjbG9uY1NJOTZ4V3ZNbHhVOWdWNjItbw?oc=5","date":"2026-03-12","type":"pipeline","source":"Business Wire","summary":"Foundation Medicine Launches Whole Genome Sequencing Germline Test for Research Use to Accelerate Biopharmaceutical Research and Therapy Development Beyond Oncology - Business Wire","headline":"Foundation Medicine Launches Whole Genome Sequencing Germline Test for Research Use to Accelerate Biopharmaceutical Rese","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5pZXpPVm1HZnhad2xHS00zVGdtUjRHcnFNZ2hlLVlQYzlMay1BSEZVaWg0SW9GT0NWU0Ywd1g2QnU0ZWRpZGhQTHBvVVRLcndIdkhoVUtHYW1wdk1VaUxj?oc=5","date":"2026-01-06","type":"trial","source":"nature.com","summary":"Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study - nature.com","headline":"Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE54WmRXNW9SZFNzUUplQmRnc0xsR1RKMHFFOC16eVNEbEJnWWFKVy1lc05nTXBva0hrMmRGUzVoN0pGeHV0Zmw0UTNMOVdIVEFTWlY1ZC12NnhIRnhCS09nbXB0ZE5oQ2hkYTdka2oxclFVQQ?oc=5","date":"2025-12-14","type":"pipeline","source":"Wiley","summary":"Physiologically Motivated Sequential Population Modeling of Albumin Trends and Vedolizumab Pharmacokinetics for Pregnancy Dosing Regimen Optimization - Wiley","headline":"Physiologically Motivated Sequential Population Modeling of Albumin Trends and Vedolizumab Pharmacokinetics for Pregnanc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE55V29qRVhLcjd6bzJza09YWGROZE4yaWtlWkE5MVljQm9JaXZxeURVRDZkRWloUEFkUEhJVmp0Y0t0WUlXYm5rcVUxWGxNWURYRGVTU3puUEFHTE1CZGxF?oc=5","date":"2025-11-08","type":"pipeline","source":"nature.com","summary":"Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology | British Journal of Cancer - nature.com","headline":"Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQLXVLZWdsWG9SUktFbUU0Y0l2YlJnMWtxLXlxSF9DaGs2VHBlYUN1ZmRVWFF4ZjZtblNlVVJ5ZE5iU3MwVWlOVFB3akpETnJsYU5xdzRtQTNidE1BdnhUMnJLclpTU2taTDBOQ01CT0ZHN20wMkdUUVQyZm9HZTdGTXdyeF93Y3RQb2JMcQ?oc=5","date":"2025-10-01","type":"pipeline","source":"Pharmaceutical Technology","summary":"Orphan drug landscape in the 7MM: launch patterns, market trends, and HTA insights - Pharmaceutical Technology","headline":"Orphan drug landscape in the 7MM: launch patterns, market trends, and HTA insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9IN19NVjliVVNmUTFSWFpDN1FlbXBkTkJBV01tRlhvakE5X0dNTFc2UEhHOWQ3ZGo5a2M2eThBZVJkWXNESTBNRWlsdGY5OXhTMlplaDVsZ0NjRWpBR3NV?oc=5","date":"2025-07-29","type":"pipeline","source":"nature.com","summary":"Safe model based optimization balancing exploration and reliability for protein sequence design - nature.com","headline":"Safe model based optimization balancing exploration and reliability for protein sequence design","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOaHBvMDA3Tk9SZXRFNEtlYmdTMFRiX1FkUjRlaXBDTndSMFgxSWFjR1h1LTRXaDJEZ3M1WlNXVHk3RmV4WGxPRGVlUU5zYlZ6amZRQWZzZjY2LWxiQndySjJBWlA1ZHpqWGxLMzJPR01iQk9xdEMzcjJzbkRXRllsZFVQa252U1BoUDZ3XzllZi1uVklU?oc=5","date":"2025-04-24","type":"pipeline","source":"Grand View Research","summary":"NGS-based RNA-sequencing Market | Industry Report, 2030 - Grand View Research","headline":"NGS-based RNA-sequencing Market | Industry Report, 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1UN1czcUdNS1RON2MtTHFGM1o1VFFjZDh5alpmZkloQl93ZmluZ1FSRjJSMVdMeUtGOG12NnYzTW14bDlJZE53THZ4Ukl4YVVYWFltSjhQNzcwd3REWFJVTFVRM3NDcUxwcVhwZXNNZ0JXTTNlYjZwM0ZfWQ?oc=5","date":"2025-04-04","type":"pipeline","source":"Wiley","summary":"Customized Hydrogel System for the Spatiotemporal Sequential Treatment of Periodontitis Propelled by ZEB1 - Wiley","headline":"Customized Hydrogel System for the Spatiotemporal Sequential Treatment of Periodontitis Propelled by ZEB1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPQzVZNGVxajdIT2xuNnlIeGlIMkNwLUo5dHB5NE5FS09NME5FaHdxU0N1RFdGT3poUUdtU3RqM2R0ZGdXVWhGRGZ4dzVDZG9uTndsSHZucTdpTUpwQXdITjdzX0tSU25DWUdvXzNzWDA2T19wY3NZNDd0MjNjZ0tpZmlLcFFNbW1OQ2M5eVhRNjk1dE5OZGs2bHNMQjRRX3NacWJrNmw0MmhnV3ZHSWR1N1JMT0VCbjh0OW5MeWxHRlpadw?oc=5","date":"2023-09-25","type":"pipeline","source":"Fierce Pharma","summary":"Why Pharma Should Pay Attention to – and Be Part of – Rapid Whole Genome Sequencing Advancement - Fierce Pharma","headline":"Why Pharma Should Pay Attention to – and Be Part of – Rapid Whole Genome Sequencing Advancement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxOcDNHQUttdkhOQkIwTXB1MkdWSWs0bkJjY3FKUHI3N2xtdm5OMy14WFRwWkRQVENVdG1ySS14WXN3WnloNTlSVkZpZ18wUGhzeUFPQ0ZxMW5RQmJ3MEVEYUZBVGFBMUR3UGxHVEVlYUVvY2owVVB2YmVkRnZXcHN5cGRzb3VkQWpjb09ocFJsYUcwejk4UXdTT3ZvWmxPVG5FYk16SFVwMTJBMzRCbUo4TFJtdl81bFM1eDdaYWl6d0ZTekdZS0plLUx4Q19IYjhZeVJLeg?oc=5","date":"2023-04-14","type":"pipeline","source":"Health Policy Watch","summary":"Pharmaceutical CEOs to G7: Protect Intellectual Property Rights and Pathogen Access in WHO Pandemic Accord - Health Policy Watch","headline":"Pharmaceutical CEOs to G7: Protect Intellectual Property Rights and Pathogen Access in WHO Pandemic Accord","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxQZnRvLWdoaENkdjhIcmNfMHMtcnM5YVFwMW5XNk05YU4yNlpreXJjOE5MYWVhRkp3U012UkxyUUZrZ2Rlc2RTVzc2OEF5SkZ2WlBKT2RYaXZGNUhST29ub0pXbjkxei1leDM0VFo3bWRONm5ZOTdTOTBrYlRUOWo2aEsxVkVDVXRJR05FQ1JwSWFUQUMxVFhXaHBsRjVOM3M1RWVfTDZxS2dYNE93SzZ3YjZ4VF9TcW5WY3dVS2xsSW5sLTh6ZjBXVm9xTUJJRjZ3S1pUWEZjN21Ca2prT0dJaU1qN3pucVpOOHNPS29mOHhzYWZaQjNLUHJRaVhDNnJGUi1pWnZxcw?oc=5","date":"2021-06-21","type":"pipeline","source":"2 Minute Medicine","summary":"Overestimation of Sequential Organ Failure Assessment scores in Black populations may lead to deprioritization during public health emergencies - 2 Minute Medicine","headline":"Overestimation of Sequential Organ Failure Assessment scores in Black populations may lead to deprioritization during pu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNeUpxcVJQM0dGMDVCVy1Ha2ViQkhWUWc2QnE1UUZ4OEplbXczaktpWUVZaUZCYWhQeGZLOGdBdWRuSUR1WURhYkxlcW1oN0VKYS1VQmc0RjRMVHgxdTZmTFhhd3hqS1hOVHNMSzQ0QjlpOXJLZ2ZVMzlfWG5fTVZoYThsRzl5eVliYmh6VUNaLVVtZXJNbWcwcWRKTUI?oc=5","date":"2019-10-15","type":"pipeline","source":"Contract Pharma","summary":"Tedor, Sequential Enter Clinical Manufacturing Pact - Contract Pharma","headline":"Tedor, Sequential Enter Clinical Manufacturing Pact","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":2,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}